Boswellia (Indian frankincense).

Boswellic acids block 5-lipoxygenase, the enzyme that converts arachidonic acid into pro-inflammatory leukotrienes, while curcumin dampens the parallel cyclooxygenase arm of the same cascade. Covering both principal branches at once is the long-standing reason the two are formulated together to support a normal inflammatory response in joints.

Boswellia inhibits the 5-lipoxygenase enzyme, while EPA competes with arachidonic acid as that enzyme's raw material and shifts its output toward the much milder 5-series leukotrienes. Acting on the enzyme and its substrate together eases the same leukotriene arm from two angles and supports the body's normal resolution of inflammation.

In the body GLA is converted to DGLA, whose 15-hydroxyl metabolite quiets 5-lipoxygenase and leukotriene formation, the same step boswellic acids block directly. Both nudge the eicosanoid balance away from the pro-inflammatory leukotriene branch, supporting a normal inflammatory response.

Bromelain is a proteolytic enzyme acting on kinin and prostaglandin signalling, separate from the 5-lipoxygenase step boswellic acids occupy.

Gingerols act on the cyclooxygenase branch while boswellic acids act on the leukotriene branch of arachidonate metabolism.

Boswellic acids are lipophilic and absorb several times better with fat present. A lipid carrier substitutes for dosing with a fatty meal.

Phospholipids keep the resin acids dispersed through the intestinal lumen so more of the dose meets the mucosa. Phytosome-style boswellia deliveries are built on this.

Piperine slows glucuronidation and intestinal efflux transport, both of which cap systemic boswellic acid exposure.

Glucosamine supplies the amino sugar backbone for cartilage glycosaminoglycan synthesis while boswellic acids act on eicosanoid signalling.

Chondroitin is a structural glycosaminoglycan of cartilage and slows matrix-degrading enzyme activity.

MSM supplies sulfur for glycosaminoglycan sulfation and glutathione synthesis in connective tissue. Boswellia contributes no sulfur.

Quercetin damps lipoxygenase activity and mast cell mediator release, overlapping the enzyme step boswellic acids act on. The effect is additive rather than independent.

Salicin becomes salicylate, which acts on cyclooxygenase and on normal platelet aggregation. Stacked with boswellia and the marine oils usually alongside it, the effect on normal clotting adds up.

Collagen peptides deliver proline-hydroxyproline dipeptides that reach connective tissue and signal matrix synthesis. Boswellia acts on signalling around the matrix, not on its supply.

Boswellic acids are large lipophilic triterpenes with poor aqueous solubility, and complexing them with phosphatidylcholine produces a phytosome that disperses far better in the gut. A 2022 study in adults used exactly this lecithin-based delivery form rather than plain extract. Any result from such a product belongs to the delivered form, not to the raw resin.

Vitamin D3 is fat soluble and is normally taken with a fat-containing meal, the same condition that raises boswellic acid absorption, so the two are convenient together. Vitamin D also supports normal muscle function and normal bone maintenance, which sits alongside a joint comfort formulation rather than duplicating it. There is no combination trial, so this is formulation logic and shared absorption conditions.

Hyaluronic acid is a core component of synovial fluid and contributes to its viscoelastic behaviour, a structural role entirely separate from the enzymatic route boswellic acids take. Products aimed at joint comfort and mobility routinely carry both for that reason. The two do not compete for absorption.

Astaxanthin is a lipid-soluble carotenoid that partitions into membranes and, like boswellic acids, needs dietary fat to absorb reasonably. Both are commonly delivered in an oil or lipid matrix, so they share a vehicle. The pairing has not been studied together in people.

Catechins and boswellic acids both suppress NF-kB-driven transcription in cultured cells, though through different upstream steps. Neither has been tested against the other in a joint human trial. The overlap is mechanistic and belongs on that footing.

Carnosic acid and carnosol from rosemary inhibit inflammatory signalling in cell work and are lipophilic diterpenes with absorption behaviour similar to boswellic acids. A 2025 review of anti-inflammatory Indian herbs discusses boswellia alongside other plant actives on shared molecular targets. The evidence is preclinical and the pairing is a formulation convention.

Boswellia and ashwagandha appear together in classical Ayurvedic joint preparations, a pairing that predates any controlled evidence. Withanolides and boswellic acids are both lipophilic triterpenoid-class compounds handled similarly on absorption. Read it as traditional practice rather than as a tested combination.

Pine bark procyanidins suppress inflammatory mediator production in cell and small human studies, a different chemical class from the pentacyclic triterpenes of boswellia. The two are combined in joint comfort products on that complementary rationale. No combination trial has been run.

Boron influences the handling of calcium, magnesium and vitamin D and is a common minor component of joint formulations. Its mechanism has nothing to do with the lipoxygenase route boswellic acids take, so the two are additive rather than overlapping. Human evidence for the pairing is absent.

Ascorbate is the required cofactor for prolyl and lysyl hydroxylase, the enzymes that stabilise the collagen triple helix, so it supports the structural side of connective tissue while boswellia acts on inflammatory signalling. A phase II study of a multi-component product combined boswellic acid, curcumin, artemisinin and vitamin C in one spray, which shows the pairing in commercial practice rather than isolating either agent. The cofactor relationship itself needs no trial.

St John's wort is a potent inducer of CYP3A4 and P-glycoprotein through pregnane X receptor activation, which accelerates clearance of many co-administered lipophilic plant compounds. Boswellic acids are already poorly bioavailable, so anything that raises their clearance works against the formulation. This is established pharmacology and is a reason to separate the two rather than combine them.

Resin extracts are commonly paired with proteolytic enzyme blends in joint products, the same convention that put bromelain next to boswellia for decades. The rationale is systemic enzyme absorption, which remains contested. This is formulation practice, not a demonstrated interaction.